Navigation Links
Researchers report new understanding of role of telomeres in tumor growth
Date:8/31/2011

Philadelphia, PA, September 1, 2011 The first report of the presence of alternative lengthening of telomeres (ALT) in cancers arising from the bladder, cervix, endometrium, esophagus, gallbladder, liver, and lung was published today in The American Journal of Pathology. The presence of ALT in carcinomas can be used as a diagnostic marker and has implications for the development of anti-cancer drug therapies.

Telomeres are nucleoprotein complexes located at the ends of chromosomes. During normal cell division, these telomeres become shorter with each division, potentially resulting in cell death. In some cancers, however, this shortening is counteracted by the ALT mechanism, thus allowing the unlimited growth of the cancer cells.

"The present study offers a springboard to guide future investigations in larger cohorts that specifically focus on the tumor types exhibiting ALT to more precisely determine the prevalence and potential prognostic value of this phenotype," commented lead investigator Christopher Heaphy, PhD, a postdoctoral research fellow at The Johns Hopkins School of Medicine.

"These results may have therapeutic consequences, given that cancers using the ALT pathway are predicted to be resistant to anti-telomerase therapies, some of which have entered phase I/II clinical trials. Further understanding of the molecular mechanisms of ALT will be paramount in designing novel anti-cancer therapeutics targeting cancers utilizing the ALT pathway," observed corresponding author Alan K. Meeker, PhD, Assistant Professor of Pathology at Johns Hopkins.

Meeker and co-investigators have assessed the prevalence of the ALT mechanism in a wide range of human cancer subtypes. Analyzing 6,110 tumor samples from 94 different cancer subtypes, 541 benign neoplasms, and 264 normal tissue samples, researchers found that the overall prevalence of the ALT phenotype was 3.73%. It was not observed in benign neoplasms or normal tissues.

Additionally, this is the first report of ALT in medulloblastomas, oligodendrogliomas, meningiomas, schwannomas, and pediatric glioblastoma multiformes.

The authors also note that they were able to identify many tumor types that apparently may not use the ALT pathway for telomere maintenance. In particular, they assessed hundreds of cases of adenocarcinomas arising from the prostate, colon, pancreas, or small intestine and did not observe a single ALT-positive tumor.

Previous studies have shown associations between ALT status and prognosis in some tumor types. The authors suggest that further studies are warranted to assess the potential prognostic significance and unique biology of ALT-positive tumors.


'/>"/>
Contact: David Sampson
ajpmedia@elsevier.com
215-239-3171
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. Lawson researchers share in $2.2 million grant
2. NIH-funded researchers discover genetic link to mesothelioma
3. UC Davis researchers find disease-causing fat cells in those with metabolic syndrome
4. Researchers uncover source of Haitian cholera outbreak
5. VBI, Convey Computer partner to deliver technology to biomedical, life sciences researchers
6. Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment
7. UT researchers develop algorithm to improve remote electrocardiography
8. TGen and DTU researchers track source of Haitian cholera outbreak
9. UH researchers explore treatments for breast and colon cancers
10. Not so fast -- researchers find that lasting evolutionary change takes about 1 million years
11. Joslin researchers identify new target for treatment of type 2 diabetes and prediabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
Breaking Biology News(10 mins):
(Date:9/21/2017)... S.C. (PRWEB) , ... September 21, 2017 , ... ... turned bright neon green this month, the response was swift and efficient thanks ... ( RRWQG ). RRWQG is made up of more than 50 stakeholders, including ...
(Date:9/21/2017)... ... September 21, 2017 , ... Biorez, ... election of Paul Hermes, Entrepreneur in Residence at Medtronic, Inc., to serve as ... a proprietary, tissue-engineered scaffold for anterior cruciate ligament (ACL) reconstruction that is designed ...
(Date:9/20/2017)... ... September 20, 2017 , ... Cybrexa Therapeutics ... Paralkar to the role of chief scientific officer. In this role, Dr. Paralkar ... Cybrexa’s president and CEO, Per Hellsund. , “I was impressed with Cybrexa’s revolutionary ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... leading global provider of engineering, architecture, project controls, construction management, commissioning and ... today announced the unveiling of the iCON™ brand which represents the collective ...
Breaking Biology Technology: